Pictured above: Geoff, Julie and their son, Emery Shudtz. Geoff passed away from pancreatic cancer at just 35. Julie and the Shudtz family started the Fight Cancer Stay Positive foundation to honor his legacy and contribute funding for pancreatic cancer research. Read their story on page 17.
In 1998, pancreatic cancer was not on the national radar. Scant research meant patients had little cause for hope.

*The Lustgarten Foundation changed everything.*

Powered by your donations and a best-in-class research-focused strategy, the Foundation quickly became a major influencer in the pancreatic cancer community. We provide two-thirds of the world’s private funding for pancreatic cancer research from organizations focused solely on this disease. Lustgarten-funded research has been a part of nearly every significant advancement in the fight against pancreatic cancer. Through the five dedicated Lustgarten pancreatic cancer research labs, scientists are studying every possible route to save patients’ lives and are paving the way toward earlier detection and better treatment options.

Each step closer to developing a cure for pancreatic cancer is cause for celebration. And each new discovery along the way creates a ripple effect of hope, inspiring both patients and scientists alike.
Leadership is an action, not a position.
DEAR FRIENDS,

As we planned for 2020, a global pandemic was not on the list of challenges we considered. We hope you and your loved ones are safe and well; if you or your family have been ill or otherwise negatively impacted by COVID-19, we wish you good health and better days ahead.

Under normal circumstances, pancreatic cancer is difficult and complex. From the initial diagnosis to the arduous treatment protocols and even Lustgarten-funded research studies, everything related to pancreatic cancer was hampered by and made even more difficult when the coronavirus exploded in early 2020. Yet, we persisted. We marvel at the strength and resilience of the pancreatic cancer community, which has only bolstered our resolve to search out, fund and accelerate innovative, collaborative and groundbreaking research to save lives.

We are acutely aware pancreatic cancer won’t stop for a global pandemic. Every day, approximately 170 Americans are diagnosed with this devastating disease. So, we pushed forward. Andrew Lustgarten was elected Chairman of the Board of Directors to continue his father, Marc Lustgarten’s legacy, in January. Andrew has served on the Board since 2001 and succeeds Dr. Robert F. Vizza, who retired in 2020. Dr. Vizza, the Lustgarten Foundation’s first President and CEO and later Executive Chairman of the Board of Directors, was the driving force behind our success and will remain as Chairman Emeritus.

Hope is the essence of Lustgarten Foundation research, which continues to advance with groundbreaking discoveries despite the unprecedented constraints and obstacles presented throughout the year. As you read this report, please note our new clinical trials, new collaborations and new developments in early detection and treatments that will improve patient outcomes. We look forward to sharing our continued research progress with you throughout 2021. Cheers to you, our Lustgarten Foundation family, to hope and to a brighter 2021!

With gratitude,

ANDREW LUSTGARTEN  
Chairman of the Board of Directors, Lustgarten Foundation;  
President and CEO, MSG Sports;  
President, MSG Entertainment

LINDA TANTAWI  
CEO, Lustgarten Foundation

KERRI KAPLAN  
President, Lustgarten Foundation
STRETCHING THE BOUNDARIES OF SCIENCE

Major medical breakthroughs could not happen without the generosity of clinical trial participants. Some patients are living longer today thanks to past trial volunteers.

RESEARCH

CLINICAL TRIALS OFFER INSIGHT INTO FUTURE OF PERSONALIZED TREATMENTS & IMMUNOTHERAPY

Clinical trials hold the promise of discovering new treatments at an accelerated pace to improve patient outcomes.

Dr. Robert F. Vizza Lustgarten Foundation
Clinical Accelerator Initiative (CAI)

The CAI is a new, groundbreaking project designed to shorten the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science and employing cutting-edge biomarkers.

These “smarter” clinical trials will generate large volumes of data that scientists can use now and in the future. Even if a trial fails, the data will be used to inform and improve future clinical trials and expedite new treatments.

Recognizing the significant advancements made possible by his steadfast and strategic leadership, the CAI is named in honor of Dr. Robert F. Vizza, who led the Lustgarten Foundation as the first President and CEO and, later, as Executive Chairman of the Board of Directors until his retirement in 2020. During his 22-year tenure, Dr. Vizza pushed relentlessly to move science from the laboratory into the clinic, where it could have the most impact on patients.
TRANSLATIONAL ADVISORY GROUP

The newly formed Translational Advisory Group, led by Chief Medical Advisor Elizabeth Jaffee, M.D., will guide the Clinical Accelerator Initiative by identifying, reviewing and developing the best translational projects to impact patient care in the clinic. This group includes renowned experts who are identifying the most innovative concepts and potential therapeutic approaches for all stages of pancreatic cancer and accelerating the testing of these new concepts.

The Translational Advisory Group is building a network of sites to execute the proposed research in small clinical trials of 10-20 patients each. These science-driven studies could dramatically inform research, enabling investigators to quickly determine if patients are responding to specific treatment approaches and why—information that will help us to continually enhance our approach in clinical trials and ultimately, clinical care.

In FY2020, the Lustgarten Foundation laid the groundwork for the first two trials to be conducted through the CAI. These exciting new clinical trials are focused on improving treatments and outcomes for patients with late-stage pancreatic cancer.

Translational Advisory Group members represent the following institutions:

Dana-Farber Cancer Institute
Duke University
Johns Hopkins
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Northwell Health
NYU Langone
Oregon Health & Science University
UC San Diego
Yale University

“Based on the success of the Lustgarten Foundation’s past research efforts, there are now more opportunities than ever to test new potential therapies in the clinic. The research conducted through the Clinical Accelerator Initiative will offer patients and their families newfound hope as we pursue life-changing discoveries.”

—Elizabeth Jaffee, M.D.
Chief Medical Advisor

Trial 1

PASS-01
(Pancreatic Adenocarcinoma Signature Stratification for treatment)

Start date: 2020
Trial size: 150 Stage IV metastatic pancreatic cancer patients
Trial locations: Princess Margaret Cancer Centre, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute and Northwell Health

Researchers are working to maximize the response to standard, first-line chemotherapy and to improve patient outcomes by comparing two standard-of-care chemotherapy regimens (Gemcitabine and Abraxane, and modified FOLFIRINOX). For each trial participant, researchers develop an organoid—a 3D cell culture of a patient’s specific tumor—and analyze its genetics, biology and drug sensitivity to determine the most effective chemotherapy regimen for each patient. If successful, this trial can pave the way for the use of organoids to personalize therapies for metastatic pancreatic cancer patients.

The critical organoid work for this trial is being conducted at the newly opened, state-of-the-art clinical testing facility at the dedicated Lustgarten Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory.

This trial is funded through the Gail V. Coleman and Kenneth M. Brunetel Organoids for Personalized Therapy Grant.

These generous contributions significantly advance research from the laboratory to the clinic, where it can have a pivotal impact on patients’ lives.

Trial 2

Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Start date: 2020
Trial size: approximately 30 previously treated Stage IV metastatic pancreatic cancer patients
Trial Locations: Dana-Farber Cancer Institute, Johns Hopkins

Immunotherapies have had limited success in treating pancreatic cancer. Now, however, researchers are focusing on combinations of drugs that may overcome the barriers limiting the effectiveness of these drugs in pancreatic cancer. One example is a trial testing previous research suggesting treatment with a stem-cell mobilizer (Plerixafor) in combination with a PD-L1 inhibitor (Cemiplimab) will activate a patient’s own tumor-killing T cells to shrink pancreatic tumors. This trial has started enrolling patients and will open the door to more promising immunotherapy treatment options for pancreatic cancer patients. The trial is based on research led by Lustgarten-funded Distinguished Scholar Dr. Douglas Fearon.

This trial is funded by the Stephen and Nancy Grand Philanthropic Fund.
While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.

THE RESEARCH MUST GO ON

While 2020 was a daunting year for many—especially for pancreatic cancer patients who needed treatment during a global pandemic—Lustgarten researchers rallied together to continue the progress that’s been made in pancreatic cancer research for patients and their loved ones. Scientists and staff members at our dedicated labs did everything they could to ensure their groundbreaking work continued, from coordinating a complicated tangle of staff schedules and lab space to maintain distance and safety, to handling complex logistics and resources for testing and analysis, to collaborating via email or over Zoom.
Pancreatic cancer research is moving faster than ever before, and Lustgarten-funded researchers are at the forefront of the most promising breakthroughs. The Lustgarten Foundation is the only non-profit to fund five Dedicated Pancreatic Cancer Research Labs, including the newest clinical lab at Johns Hopkins added in 2020. These labs are united in their shared goals of increasing collaboration between world-renowned pancreatic cancer researchers, exploring promising avenues for understanding and treating pancreatic cancer and improving patient outcomes.

**DANA-FARBER CANCER INSTITUTE**
*Boston, Massachusetts*

**Lead by:**
*Brian Wolpin, M.D., MPH*

**OVERVIEW:**
**Advancing Translational Research**

Under the leadership of Dr. Brian Wolpin, the Lustgarten Laboratory at Dana-Farber is a critical hub for advancing research from the laboratory to the clinic (a process known as pancreatic cancer translational research), initiating scientifically-driven clinical trials and identifying new approaches to early detection. Dr. Wolpin and his team are also analyzing pancreatic cancer subtypes to understand mechanisms of drug resistance and the genetic drivers that determine each subtype.

“This year, we’ve made significant progress in understanding an inherited risk for pancreatic cancer in particular. If we can learn who’s at risk for pancreatic cancer by sequencing the DNA of patients, then we can use new blood tests and scans to find and treat cancer early. We can also use that information to devise new therapies through what’s sometimes called personalized medicine.”

---

**JOHNS HOPKINS**
*Baltimore, Maryland*

**Lead by:**
*Bert Vogelstein, M.D.*

**OVERVIEW:**
**Furthering Early Detection and Therapeutics**

Directed by Dr. Bert Vogelstein, the Lustgarten Laboratory at Johns Hopkins is using its expertise in early detection to discover pancreatic cancer at an earlier stage, when patients may be surgical candidates, and is developing new therapeutic approaches based on genetic alterations.

Researchers led by Dr. Vogelstein are working on CancerSEEK, a powerful blood test capable of detecting the early presence of pancreatic cancer and several other types of cancer, and CompCyst, a fluid-based test to help physicians diagnose pancreatic cyst type and to determine if surgery is necessary.

“The Lustgarten Foundation was one of the first private foundations to recognize the importance of early detection, and to recognize that prevention is better than a cure whenever it can be practiced. They were way ahead of the crowd for a long time as the only foundation convinced this was one of the major ways forward.”

---

**JOHNS HOPKINS**
*Baltimore, Maryland*

**Lead by:**
*Elizabeth Jaffee, M.D.*

**OVERVIEW:**
**Advancing Immunology**

The Lustgarten Foundation Pancreatic Cancer Research Clinical Laboratory at Johns Hopkins led by Dr. Elizabeth Jaffee is working to bring novel therapies for pancreatic cancer to the clinic as quickly as possible. Building on decades of experience and expertise in the immunology of pancreatic cancer, Dr. Jaffee and her team are focusing on immune therapies and developing approaches to bring the benefits of this revolutionary approach to treating tumors to pancreatic cancer.

“We have technologies that allow us to take a small piece of cancer tissue from a patient, study its genetics and proteins, and understand how that tumor is interacting with the immune system and with other systems in the body, and come up with possible therapies that may benefit those patients. This is where cancer research is going, and we could not do that even five years ago.”

---

**MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT)**
*Cambridge, Massachusetts*

**Lead by:**
*Tyler Jacks, Ph.D.*

**OVERVIEW:**
**Merging Technology and Engineering**

The Lustgarten Laboratory at MIT is leveraging its unparalleled expertise in cancer biology and engineering to advance pancreatic cancer research. Led by Dr. Tyler Jacks, the laboratory is studying the genetic events contributing to cancer development and examining the immune responses to the disease using molecular profiling to identify tumor mutations.

“Over the last year, we’ve built new model systems in mouse models of the disease that allow us to study with a level of precision that has not previously been possible. We’re currently running preclinical trials in those model systems to see which drugs and drug combinations work best to bring about a proper immune response against pancreatic cancer. If we are successful, and I’m hopeful that we will be, we can then move those concepts and treatments into clinical trials relatively quickly, with the help of the Lustgarten Foundation.”
CancerSEEK Accelerates Early Detection

Lustgarten-funded research at Johns Hopkins played an instrumental role in the development of an early detection blood-based test called CancerSEEK that can identify the presence of multiple cancers. A landmark study of the test, released in April 2020, shows promising results for earlier detection as part of routine medical checks, enabling potentially curative treatment that could change patient outcomes.

The DETECT-A study, conducted by Johns Hopkins and Geisinger Health, enrolled more than 10,000 women with no prior history of cancer. The purpose was to identify multiple cancer types in asymptomatic individuals using an early version of CancerSEEK. The study found that the test more than doubled the number of cancers that were first “screen-detected” and identified undiagnosed cancers in 10 different organs (including seven with no current standard-of-care screening). The technology behind CancerSEEK was licensed to Thrive, and based on the success of DETECT-A, Thrive was recently acquired by Exact Sciences. This partnership brings additional resources and expertise to accelerate the development and commercialization of CancerSEEK.

Artificial Intelligence is Key to Detecting Pancreatic Cancer Earlier

Scientists from a broad range of disciplines at Johns Hopkins are using artificial intelligence to detect pancreatic cancer earlier. Through their research, they’ve trained computers to recognize patterns in medical images to detect pancreatic tumors on CT scans. Researchers are working to detect on CT scans pancreatic tumors measuring one centimeter or less, when they may be missed by a diagnostician, so diagnosis and subsequent treatment can be started much sooner. This research is part of the Foundation’s overall FELIX project (named for Harry Potter’s Felix Felicis, also called “Liquid Luck,” a magical potion that makes the drinker lucky) focusing on developing new early detection methods using artificial intelligence.

New CompCyst Test Can Prevent Unnecessary Surgeries

The Lustgarten-dedicated laboratory at Johns Hopkins is developing a test called CompCyst, which combines clinical, radiological, genetic and protein marker information to classify pancreatic cysts and determine which ones require surgery. The Lustgarten Laboratory at Johns Hopkins is working to further develop CompCyst into a clinically approved test.

David Tuveson, M.D., Ph.D.
Cold Spring Harbor Laboratory

“I’m very hopeful about the future of pancreatic cancer patients as we begin moving our science into the clinic. We have the doctors, the scientists, the supporters and the patients who want to sign up for clinical trials. This is the next step in our efforts to make pancreatic cancer history and it is only possible because of Lustgarten Foundation funding.”
What gives you HOPE for the future?

Brian Wolpin, M.D., MPH
Dana-Farber Cancer Institute

“We have multiple new clinical trials that are opening now and in the next one to two years, based on the science tested in the laboratory at Dana-Farber and by other Lustgarten-funded investigators. The support that the Lustgarten Foundation has provided for the past ten years has greatly helped us advance our work in bringing new therapies to our patients. We see hope for our patients in this research, and we’re very optimistic that these trials will provide significant advances.”

Bert Vogelstein, M.D.
Johns Hopkins

“Rapidly advancing technologies have accelerated research and offered opportunities for discoveries about pancreatic cancer that were previously unattainable. In the coming years, we anticipate even more progress in understanding, detecting, and treating the disease.”

Tyler Jacks, Ph.D.
Massachusetts Institute of Technology (MIT)

“The science behind pancreatic cancer is getting better by the day. Our depth of understanding of how this disease arises and progresses is much, much deeper today than it was just a few years ago. And that will definitely translate into new therapies. I’m encouraged by the fact that we’re making tremendous scientific progress, and invariably clinical progress follows. The support that we get from organizations like the Lustgarten Foundation is critical. Without it, we could not make progress.”

Brian Wolpin, M.D., MPH
Dana-Farber Cancer Institute

“We have multiple new clinical trials that are opening now and in the next one to two years, based on the science tested in the laboratory at Dana-Farber and by other Lustgarten-funded investigators. The support that the Lustgarten Foundation has provided for the past ten years has greatly helped us advance our work in bringing new therapies to our patients. We see hope for our patients in this research, and we’re very optimistic that these trials will provide significant advances.”

Elizabeth Jaffee, M.D.
Johns Hopkins

“We are rapidly converting laboratory discoveries into new treatments that are being tested in innovative clinical trials. Findings from these clinical trials help us understand how these new treatments are working in patients, and also provide important information that helps us improve their activity against pancreatic cancer. In addition, our new technologies allow us to learn much more about an individual’s cancer and response to different treatments. During the next 5 years our goal is to learn enough to be able to personalize combination treatments and make a big difference in how this disease is treated.”
PANCREATIC CANCER COLLECTIVE
The Pancreatic Cancer Collective, a joint initiative of the Lustgarten Foundation and Stand Up To Cancer, is making groundbreaking progress in identifying new ways to treat pancreatic cancer and improving outcomes for patients. The Collective is conducting nearly 30 clinical trials led by more than 400 research investigators at approximately 70 participating institutions.

New Clinical Trial Finder
A new, interactive tool on the Collective’s website, created in 2020, provides details and locations of clinical trials around the country, enabling pancreatic cancer patients and their loved ones to easily find information on current and ongoing research for which they may be a candidate.

30 CLINICAL TRIALS
400 RESEARCH INVESTIGATORS
70 PARTICIPATING INSTITUTIONS
Exploiting DNA Repair Gene Mutations in Pancreatic Cancer
Principal Investigators: Alan D'Andrea, M.D. and James Cleary, M.D., Ph.D., both from the Dana-Farber Cancer Institute

Immunotherapy Targeting Mutant KRAS
Principal Investigators: Robert Vonderheide, M.D., D.Phil., Abramson Cancer Center at the University of Pennsylvania, Elizabeth Jaffee, M.D., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Beatriz Carreno, Ph.D., University of Pennsylvania

Molecularly Targeted Radionuclide Therapy via the Integrin AlphaVbeta6
Principal Investigators: Julie Sutcliffe, Ph.D. and Richard Bold, M.D., both from the University of California, Davis

Targeting SHP2 in Pancreatic Cancer
Principal Investigators: René Bernards, Ph.D., Netherlands Cancer Institute, Hana Algül, M.D., Ph.D., Technical University of Munich and Emile Voest, M.D., Ph.D., Netherlands Cancer Institute

These projects encompass several different approaches, from targeted delivery of radiotherapies (Drs. Sutcliffe and Bold), to vaccines against mutant KRAS, the mutation found in more than 90% of pancreatic cancers (Drs. Vonderheide, Jaffee and Carreno), to combination strategies to address mutations with DNA damage repair deficiencies (Drs. D'Andrea and Cleary), to KRAS activation (Drs. Bernards, Algül and Voest).

The Collective also awarded two grants for computational approaches using artificial intelligence to mimic human reasoning and identify individuals in the general population who are at high risk for pancreatic cancer.

“New Therapies Challenge” Grants
Four projects supported by the Collective’s "New Therapies Challenge" grants have made it through the second round of funding, enabling researchers to take potential treatments into clinical trials and accelerate the discovery of new therapeutic options. These innovative ideas represent a bold step forward in helping patients and will support nine new clinical trials, five of which are already underway. The projects are:

- Exploiting DNA Repair Gene Mutations in Pancreatic Cancer
- Immunotherapy Targeting Mutant KRAS
- Molecularly Targeted Radionuclide Therapy via the Integrin AlphaVbeta6
- Targeting SHP2 in Pancreatic Cancer

These projects encompass several different approaches, from targeted delivery of radiotherapies (Drs. Sutcliffe and Bold), to vaccines against mutant KRAS, the mutation found in more than 90% of pancreatic cancers (Drs. Vonderheide, Jaffee and Carreno), to combination strategies to address mutations with DNA damage repair deficiencies (Drs. D'Andrea and Cleary), to KRAS activation (Drs. Bernards, Algül and Voest).

The Collective also awarded two grants for computational approaches using artificial intelligence to mimic human reasoning and identify individuals in the general population who are at high risk for pancreatic cancer.
Identifying Novel Therapeutic Approaches

In our ever-expanding effort to ensure a robust and flourishing pipeline of potential treatments, we launched a new Therapeutics-Focused Research Program, which will award grants to research aiming to:

- Learn how the stroma—the supportive tissue surrounding the pancreatic tumor—may help protect tumors from the immune system and resist therapies.
- Understand and discover how to block the inflammatory signals that can lead to pancreatic cancer and other pancreatic diseases in response to environmental causes.
- Determine ways to stop tumor cell growth by blocking the abnormal metabolic pathways used by pancreatic cancer cells.
- Prevent the spread—or metastasis—of cancer by isolating metastatic triggers in cancer cells and the stroma.

Through this new grant program, the Lustgarten Foundation will enable collaboration and identify novel therapeutic approaches and/or drug targets that will expand our collective understanding of pancreatic cancer treatment.

Raul Rabdan, Ph.D., MSc, at Columbia University, along with Núria Malats, M.D., MPH, Ph.D., at the Spanish National Cancer Research Centre, will develop a collection of biomarkers for pancreatic cancer which will be obtained from large clinical and molecular datasets with multiple cohorts. This is a high-risk, high-reward project that, if successful, will integrate clinical, genetic and microenvironmental factors to revolutionize screening and risk prediction for pancreatic cancer.
Bob Minetti plans to play a lot of golf in the next year. At 73 years old, the former professional fundraiser is also an avid walker, reader and bridge player. But when he received a Stage III pancreatic cancer diagnosis in 2016, he didn’t know how long he could continue doing the things he loved.

A mysterious pain in Bob’s stomach and low back had led to an initial diagnosis of pancreatitis, but his own deep family history of cancer inspired him to push for more information. He recalls advice from an uncle who had survived both kidney and bladder cancer: “He told me that unlike most men, he paid attention to what his body was telling him, and he wasn’t scared to go to the doctor.” Bob’s quest for answers led to additional testing, which revealed a malignant tumor lodged against a major vein.

Bob met with a radiation oncologist at Massachusetts General Hospital and learned about a new clinical trial sponsored by the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer. He joined the trial as #27 in the pilot test group.

The trial combined a powerful chemotherapy called FOLFIRINOX with an older blood pressure medication, losartan, which is believed to soften the hard outer surface of pancreatic tumors, making the tumor more vulnerable to chemotherapy. Bob’s tumor responded dramatically, shrinking “like butter in the microwave,” as one of his doctors described. After six months of chemotherapy and proton beam radiation treatments, Bob underwent a complex Whipple surgery to resect the tumor. Four years later, Bob’s oncologist sees no signs of cancer and says he doesn’t need to come in for scans anymore.

Among patients in the trial whose pancreatic tumors had initially seemed inoperable, 61% were able to have tumors completely removed. In three, the drug treatment was so effective that the surgery found no detectable cancer. The study found that overall, patients whose tumors could be removed survived a median of 33 months. The pilot study’s findings have been carried forward to a larger randomized study.

Bob’s story is shared in a series of Public Service Announcements (PSAs) promoting the Collective and clinical trial participation. The PSAs also feature actress, writer and director Keesha Sharp, who lost her mother to pancreatic cancer in 2020.

To those considering participation in a clinical trial, Bob has one piece of advice. “Do it,” he says, without hesitation. “They’re making really great strides with early diagnosis, and I’m proof of the fact that you have a fighting chance.”
VIRTUAL WALKS RAISE MONEY, AWARENESS AND HOPE

We’re grateful for the Lustgarten Foundation community’s resilience and determination to push forward with socially distanced walks and find creative new avenues for fundraising during the pandemic. With a generous $100,000 match from the Dozen Dimes Foundation and unbridled enthusiasm from volunteers and walkers, the virtual events were a resounding success. Despite navigating the limitations imposed by the pandemic, thousands of participants were united in their efforts to support pancreatic cancer research, joining in virtual walks beginning in March 2020, including the first National Virtual Walk for Pancreatic Cancer Research held on June 28. Participants donned purple t-shirts and stepped up and out—in their neighborhoods, driveways, local parks, or homes—and shared their stories on social media. Friends, families, co-workers and neighbors celebrated their collective achievements and their commitment to raising money for pancreatic cancer research.

Thank you, GenesisCare/21st Century Oncology, for sponsoring the 2020 Southwest Florida Pancreatic Cancer Research Walk.

Thank you, Moffitt Cancer Center, for sponsoring the Tampa Pancreatic Cancer Research Walk in 2019 and 2020.

12,000 WALKERS
981 PARTICIPATING TEAMS
Together, step by step, we will achieve the Foundation’s vision of a world in which there is a cure for pancreatic cancer and patients can enjoy their lives.

Thank you, Northwell Health! Northwell Health was the exclusive sponsor of the 2020 virtual walks in the New York metropolitan area, including our first New York Virtual Walk. We were so grateful to team up with Northwell Health for the second year to support pancreatic cancer patients!

$2.85 MILLION RAISED IN 2020
$47.4 MILLION RAISED SINCE INCEPTION
TEE'D OFF AT CANCER
On September 9, 2019, a full field of golfers hit the links at the Old Oaks Country Club for Lustgarten’s Tee’d Off at Cancer tournament, organized by the Wallack family. Participants played 18 holes on the beautiful rolling greens of the championship course, raising nearly $180,000. Thank you to (left to right) Dr. Bruce Stillman, Cold Spring Harbor Laboratory and Lustgarten Scientific Advisory Board member; Dr. David Rivadeneira, Northwell Health Cancer Institute at Huntington; Dr. Bhuvanesh Singh, Memorial Sloan Kettering Cancer Center; and Dr. Richard Barakat, Northwell Health Cancer Institute, for joining in the event.

ROCKIN’ & ROLLIN’ FOR RESEARCH
In 2019, MSG Entertainment/MSG Sports and AMC Networks hosted the 19th Annual Holiday Rock & Roll Bash, Lustgarten’s signature fundraising event. Emcee DJ Cassidy and iconic Radio City Rockettes entertained partygoers at TAO Downtown in New York City. Guests were dressed to impress, reveling in the nightclub’s swanky vibes as they dined and danced the night away. We are so grateful to the sponsors, attendees and donors who together raised more than $1 million for research.
Supporter Spotlight:
Julie Shudtz and Kristin Shudtz
A Mantra and a Movement: Fight Cancer Stay Positive

Three weeks after Geoff’s son was born, the first-time dad received the most crushing news imaginable: he had Stage IV pancreatic cancer. The diagnosis was incomprehensible to this athletic 34-year-old. But Geoff found hope grounded in the love of family—including his newborn son, Emery—and the determination of the oncologist committed to his treatment.

“His caring nature and spirit of adventure never diminished,” shared Julie, Geoff’s wife. “He had a special gift—always the life of the party, Geoff also made you feel like you were the only person in the room.”

Geoff’s sister Kristin—a nurse anesthetist who had cared for pancreatic cancer patients—knew the road ahead would be tough. “My brother put on a brave face and he was always fighting for more time with his family,” Kristin said. “He was the best big brother in the world.”

Geoff’s late diagnosis ruled out surgery—and the disease had already spread to his liver. Geoff’s zest for living and devotion to family kept him going despite the bad news. When chemotherapy failed, Geoff joined a clinical trial testing an oral immunotherapy. Geoff and Julie had five good months together until the treatment stopped working and Geoff tried another chemotherapy. But then Geoff suffered a devastating setback—a stroke. He lost the ability to speak and move his right side. In another remarkable show of determination, he fought back again to regain the ability to talk and walk.

And when Geoff passed away 14 months after his diagnosis and just six weeks before his 36th birthday, Julie, Kristin and all of his family took solace in the time they had together—eight more precious months than predicted, thanks to significant research advancements. To honor Geoff’s life and remember his spirit, Geoff’s family created Fight Cancer Stay Positive, a foundation that—in its inaugural “Dunking for a Cure” fundraising event—raised $100,000 for the Lustgarten Foundation, despite moving to a virtual format in April 2020.

“In going through this experience, I learned to be strong and stay positive because that’s what Geoff always did,” Julie said with a full heart. “Trivial things don’t matter anymore...you quickly figure out who and what truly matters in your life.”

And one of the things that matters most to Julie and Geoff’s family now is helping other families on their own pancreatic cancer journeys. “Fight Cancer Stay Positive” was Geoff’s mantra—it was the unbreakable spirit he brought to all he went through, and the belief that enabled Geoff and Julie to plan for their future despite his diagnosis. So, it’s the fitting name they’ve given to their work to honor and remember him.

Despite her tremendous loss, Julie feels lucky Geoff received the best possible care. For her, Geoff lives on in their son, in their story and in the research the Lustgarten Foundation supports thanks to you.

Geoff and Julie (pictured above, with their son, Emery) never gave up hope.
Thank you to all the community event organizers and supporters who demonstrated that even during a pandemic, your energy, enthusiasm and commitment to fund pancreatic cancer research and save lives couldn't be stopped. You held more than 200 events, including the approximately 115 listed here which each raised at least $1,000, and you inspired your families, friends and communities to join the fight to end pancreatic cancer. We are so grateful for your generosity.

ATHLETICS
BFA Pancreatic Cancer Awareness Game in Memory of Barbara Clark
Big Deb Classic Fishing Tournament in Memory of Deborah Bailey
Canter for the Cure in Memory of Arlene Bates Toyne
Desmond Cooke 111 Mile Walk
Diamond Hill CrossFit Fundraiser
Ed Wehrman Memorial Fishing Tournament
Gumpy's Crew Kids Triathlon
Hauppauge Softball Fundraiser
Hills For Howard
Massapequa High School Basketball Alumni Game Charity Fundraiser
Port Jefferson Yacht Club Foundation Village Cup Regatta
Purple Pucks for Pancreatic Cancer Research
Sk8 to Elimin8 Cancer
Steve Koziol Memorial Salmon Derby
Steve Rickert Memorial Shoot
Swim to Cure Pancreatic Cancer
Terry Rau Sr. Pancreatic Cancer Co-Ed Washer Tournament
The Second Annual Matt Fields Memorial Spin Extravaganza
Wellesley Black Rhinos Soccer Club in Memory of Jim Santaniello

ENDURANCE
In Memory of Uncle Tim—Marine Corps Marathon
Jo and George's Just Us Jerks Tough Mudder PC Fundraiser
J.P. Steers for the Brooklyn Half Marathon
NYC Half Marathon—Michelle Bernstein, Peter Bernstein, Greg Chapin, Larry Doyle, Rachel Gerber, Caroline Kiggins, Austin Leist, Daniel Murphy, Madi Roe
NYC Virtual Marathon—Sean Rosenberg, Jack Statfeld
RJA Memorial Mighty Montauk Triathlon

FUNDRAISE YOUR WAY
Anything for Family in Memory of Murray Navarro
In Honor of Bernie Reilly
In Honor of David R. Gibson
In Honor of Philip Drucker
In Loving Memory of Michael F. Pasquale
In Loving Memory of Vivian Schneider
In Memory of Arline and Stan
In Memory of Bob Hsieh
In Memory of Brian J. Richmand
In Memory of Bubby—Gangadhar Mantravadi
In Memory of Chris Halvorson—Lacey
In Memory of Fred Hauser
In Memory of Gladys Norma Taylor
In Memory of Harriet Koretsky
In Memory of Hernando Rasay
In Memory of Jacotte
In Memory of Josef Cooper
In Memory of Linda—Our Warrior
In Memory of Michael DiLonardo
In Memory of Pedro Franco
In Memory of Ralph E. Bell Sr.
In Memory of Thomas Warren
In Memory of Yolanda Jackson Oscar "Ozzie" Snyder Memorial

GOLF
AOH Division 2 Golf Outing in Honor and Memory of Msgr. Jim Kissane
Brett Rollman Memorial Golf Outing
Camille Della Torri Golf Outing
Carol B. Smith Memorial Golf Outing
Carol Bossone Memorial Golf Tournament
Croatian American Charitable Foundation Golf Outing in Memory of Val Blaskovic
Debbie Open Golf Outing
Ed Outslay Memorial Golf Tournament
Golf Tournament in Memory of JoAnn McGovern
Hit & Run Golf
Jake's Men's Club 13th Annual Golf Outing
Joe LoCicero Memorial Golf Invitational
NAPMW in Memory of Francis Makin
Richard W. Grabowski Golf Tournament
Scramble for Shelly
Terry Hagen Memorial Golf Tournament
The Larry Golf Classic
SOCIAL EVENTS

Alpha Zeta Omega Fundraiser
Americana Manhasset Champions for Charity
Ardzley Children’s Center BBQ
Bell Silvercraft Club Fundraiser in Memory of Judy Resel
Block Party in Memory of Hester Riley
Bonnie Sollog Talent Show
Boston Scientific
No Shave November
Bring A Buck
Calf for a Cause
Chess for Cancer
Chop and Stout Month at Shoreline Brewery
Concert/Fundraiser in Honor of Elissa Queen
Facebook
Frank’s Fundraiser for Pancreatic Cancer Research
Fred Preston Charity Tournament
Gala Charity Night
Jack Greenspan Fundraiser
Judy Field Memorial Foundation Music Festival
Leonard Park Wines & Spirits Event in Honor of Joseph Larizza
Marriott RMAS Rising Stars
Musical Benefit and Tea in Memory of Serge
Nancy J. Semmel Foundation Beefsteak Dinner
Naperville Police Department No Shave November
NJ Hi-Railers Calendar Sales
No Shave November Fraternal Order of Police
Owens Charity Auction
Pancakes for a Purpose in Memory of David A. Anstadt and John Bradley
Players Brawl, LLC
Raddle the Bottoms Bluegrass and Folk Festival
Raising Hope for Others
Sal Cannizzo Memorial BBQ
Sellers Publishing, Inc. Fundraiser
Shooting for a Cure for Pancreatic Cancer
Shop for a Cause 519 Event
Stone House Nursery Father’s Day Fundraiser
Zavaros Family Fundraiser

TRIBUTE

I Love You, Mom

WALKS & RUNS

5cacia Run for Pancreatic Cancer Research at Ohio University
5K Beer Run/Walk in Memory of Beth Moore & Thomas Lesselyong
Bob Kochka Memorial 5K Run/Walk
Crush Pancreatic Cancer 5K and Chillin’ for Chili Cook-Off
Gloria’s 5K
Help Fight Cancer Walk
Lake Wallkill
Pound the Pavement for Purple 5K Run/Walk

MILLION RAISED THROUGH COMMUNITY EVENTS

$1.28 MILLION RAISED THROUGH COMMUNITY EVENTS

Ten-year-old Jack started his own virtual walk in Philadelphia, raising more than $5,000.

Sean joined Lustgarten’s NYC virtual marathon team in memory of his dad—his hero. The Lustgarten team raised $36,500 for research.
**FINANCIAL PERFORMANCE FY2020**

MORE THAN $200 MILLION IN RESEARCH GRANTS AWARDED SINCE INCEPTION

<table>
<thead>
<tr>
<th></th>
<th>FY2020</th>
<th>FY2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenue*</td>
<td>$18,773,592</td>
<td>$28,056,667</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$28,669,739</td>
<td>$39,914,538</td>
</tr>
<tr>
<td>Annual Research Expenses</td>
<td>$19,760,631</td>
<td>$24,673,145</td>
</tr>
<tr>
<td>Research Commitments Outstanding</td>
<td>$43,292,539</td>
<td>$29,710,588</td>
</tr>
<tr>
<td>Total Net Assets</td>
<td>$80,956,636</td>
<td>$90,589,555</td>
</tr>
</tbody>
</table>

* The decrease in FY2020 revenue over FY2019 revenue is primarily due to a decrease in $6.4 million in donated media and a $2 million bequest received in 2019.

The financial performance information for FY2020 represents the activity of the Foundation for the period from July 1, 2019 through June 30, 2020.

The audited financial statements of the Lustgarten Foundation are available on our website, www.lustgarten.org.

---

100% of your donation funds pancreatic cancer research.

**FY2020 TOTAL REVENUE**

- 51% Contributions $9,526,625
- 21% Gifts-in-kind $3,946,136
- 19% Events $3,519,808
- 9% Investment Income and Royalties $1,780,022

**FY2020 TOTAL EXPENSES**

- 69% Research $19,760,631
- 17% Public Education $4,739,143
- 9% Fundraising $2,828,833
- 4% Management & General $1,094,488
- 1% Professional Education $246,644

---

20 Annual Report 2020
DONORS

THANK YOU TO OUR GENEROUS DONORS, WHOSE SUPPORT ENABLES US TO FUND THE MOST INNOVATIVE RESEARCH LEADING TO NEW BREAKTHROUGHS AND ADVANCING OUR MISSION OF FINDING A CURE.

Whether you participated in a walk or community event, donated, followed our social media channels or raised awareness about this disease and the Foundation’s efforts to save lives, we are so grateful. We wish there was enough space to thank each individual, foundation, corporation and organization for your generosity. However, please know each contribution is deeply appreciated.

Founders
Bill and Ellen Bell
Cablevision Systems Corporation
Charles B. Wang Foundation
Mr. and Mrs. Frederick DeMatteis
Mr. and Mrs. Charles F. Dolan
Mr. and Mrs. James L. Dolan
Mr. and Mrs. Amos B. Hostetter Jr.
Mr. and Mrs. John T. Lockton III
The Lustgarten Family
McMullen Family Foundation
Mr. and Mrs. F.F. Randolph Jr.
Mr. and Mrs. Leonard Tow

Chairman’s Circle
$10,000,000–$50,000,000 Cumulative Since Inception
Altice USA Media Solutions
Cablevision Systems Corporation
Estate of Mary Brenneisen
The Walter B. Wriston Fund

Chief Executive’s Circle
$500,000–$999,999 Cumulative Since Inception
Bristol Myers Squibb
Eleanor Schwartz Charitable Foundation
Estate of Dorothy C. Guida
Estate of Patricia C. Galgan
FCB Health
Gibson, Dunn & Crutcher, LLP
James S. Swinehart Memorial Fund
JCPenney
Karen Zissu-Magidson Memorial Fund
Mr. and Mrs. John T. Lockton III
McMullen Family Foundation
News Corporation
Newsday

President’s Circle
$100,000–$499,999 Cumulative Since Inception
21st Century Fox
Amdocs Broadband Cable & Satellite Division
Anne & John Tatta Family Foundation
Arris
Baldor Specialty Foods Inc.
Bank of America
Barbara J. Hall Trust
Barbara Mantoni Santaniello Research Fund Inc.
Bear Stearns Companies, Inc.
Bill and Ellen Bell
Bethpage Federal Credit Union
Black Twig Communications, LLC
BNP Paribas
Boston Scientific Corporation
Brindell Roberts Gottlieb Trust
Brisbin Brook Beynon, Architects

Estate of Lucille L. Tirkfield
Estate of Maxine Stein-Kohler
Estate of Roberta Coppola
KPMG LLP
Levon Graphics Corporation
The Lustgarten Family
Mark Broxmeyer Memorial Fund
MSG Entertainment/MSG Sports
The Antoinette E. (“Mimi”) & Herman Boehm Foundation
Theodore W. Batterman Family Foundation, Inc.
Rolfe Pancreatic Cancer Foundation
Mrs. Kathryn Schulberg
Sullivan & Cromwell LLP
The Bern Schwartz Family Foundation
The Cornelia T. Bailey Foundation
The Ralph C. Marcove Cancer Research Fund, Inc.
Mr. Charles Wang

Vice Chairman’s Circle
$1,000,000–$9,999,999 Cumulative Since Inception
AMC Networks
Creative Bath Products, Inc.
Dolan Family Foundation

Mr. and Mrs. F.F. Randolph Jr.
Mr. and Mrs. John T. Lockton III
McMullen Family Foundation
News Corporation
Newsday

Estate of Mary Brenneisen
The Walter B. Wriston Fund

We wish there was enough space to thank each individual, foundation, corporation and organization for your generosity. However, please know each contribution is deeply appreciated.
The Peter Grosslight Memorial Fund
The Richard E. Capri Foundation
The Robert & Lynne Grossman Family Foundation
The Robert and Marion Schamann Brozowski Foundation
The Schwartz Family Foundation
The Spionkop Charitable Trust
The Weinstein Company
The William H. Isacoff, M.D. Research Foundation
Thomasville Home Furnishings
Metro NY
Time Warner, Inc.
Tom’s Cure Pancreatic Cancer Foundation
Mr. Leonard Tow
Turner Broadcasting Systems, Inc.
UBS Financial Services, Inc.
Mr. and Mrs. Mark Udell of London Jewelers
Verizon Communications
Viacom
Wasily Family Foundation
West New York Restoration of CT, Inc.
William Morris Endeavor
Entertainment
Willkie, Farr & Gallagher, LLP
WLNY TV 10/55
Hope and Gavin Wolfe
Suzanne and Bob Wright

This listing reflects the total amount of donors’ commitments from July 1, 2019–June 30, 2020. Please visit lustgarten.org for a listing of donors who contributed $1,000–$2,499 between July 1, 2019–June 30, 2020.

Platinum Circle
$10,000,000–$50,000,000
The Walter B. Wriston Fund

Sapphire Circle
$1,000,000–$9,999,999
Altice USA Media Solutions

Diamond Circle
$100,000–$999,999
Barbara J. Hall Trust
Dolan Family Foundation
Dr. Claude V. Greco Charitable Fund
Eleanor Schwartz Charitable Foundation
Estate of Robert Penardi
KPMG LLP
Ms. Pearl A. Lemieux
MSG Entertainment/MSG Sports
Northwell Health Cancer Institute Pancreatic Cancer Center
Paul Hastings
Peterson Family Fund at the East Bay Community Foundation
Rolfe Pancreatic Cancer Foundation
The Antoinette E. (“Mimi”) & Herman Boehm Foundation
The Benevity Community Impact Fund
The Cornelia T. Bailey Foundation
The McAdam Family Foundation

Gold Circle
$50,000–$99,999
AMC Networks
Estate of Richard A. Zingoni Foundation For A Better World, Inc.
Irving Hansen Foundation
Johnson Charitable Trust at the request of Sandy and Steve Waters, Tara and James Waters, and Anne and Jon Enberg
Las Vegas Sands Corp.
Ruth and David Levine
Mr. Mark S. Mahoney
Ms. Carolyn Mostyn
NBA Cares
Newsday
Ms. Susan G. Oberstein
Pound the Pavement for Purple 5K Run/Walk
Robert Black Charitable Foundation
Mr. and Mrs. David E. Salanson
Greg and Lynda Seck
Stephen & Mary Birch Foundation
Sullivan & Cromwell LLP
The Bern Schwartz Family Foundation
The Dozen Dimes Foundation, Inc.
The Ralph C. Marcove Cancer Research Fund, Inc.
Wasily Family Foundation

Silver Circle
$25,000–$49,999
Angiodynamics
Boston Scientific Corporation
Casino M8trix
Charter Communications
Cravath, Swaine & Moore LLP
David M. Seiden Memorial Fund
estate of Freda C. Levine
estate of Lynda M. Dembek
estate of Margaret Wilhelm
Mr. and Mrs. Ross Frankel
Mr. and Mrs. Ken Fuirst
German Masonic Charitable Foundation, Inc.
Gibson, Dunn & Crutcher, LLP
Greater Hartford Community Foundation, Inc.
Hughes Hubbard & Reed LLP
Insurance Auto
Ipsen Biopharmaceuticals, Inc.
James M. and Margaret V. Stine Foundation
James S. Swinehart Memorial Fund
Karen Zissu-Magidson Memorial Fund
Kauff McGuire & Margolis LLP
The Lustgarten Family
Ms. Charmaine Malachinski
Michael and Lori Milken Family Foundation
Dr. Felicia Pagliuca and Mr. Joe Pagliuca
Port Jefferson Yacht Club Foundation
Mrs. Barbara A. Putz
Mr. and Mrs. Peter C. Richardson
Ms. Victoria E. Schonfeld
Shostak Charitable Fund
Shutterfly, Inc.
The Gloria J. Rosenthal Memorial Fund
The Mancheski Foundation, Inc.
The Richard E. Capri Foundation
The Robert J. Bauer Family Foundation
The Warren Alpert Foundation

Lustgarten Foundation 23
Mr. Joseph P. Agazzi
Akin Gump Strauss Hauer & Feld, LLP

Andree Wildenstein Dormeuil & Roger Dormeuil Foundation
Anne & John Tatta Family Foundation
Mr. and Mrs. Ed Arnold
Big Deb Classic Fishing Tournament in Memory of Deborah Bailey
Bank of America
Benhar Office Interiors
Mrs. Linda K. Berger
Berro Family Foundation, Inc.
Bloomingdale, New Jersey Fire Department
BNP Paribas
Bonner Family Private Foundation, Inc.
Boyle Family Foundation
Ms. Barbara A. Bradley
Bright Funds Foundation
Mrs. Carolann C. Catalogne
Celgene Corporation
Mr. and Mrs. Richard L. Chadakoff
Mr. and Mrs. Thomas E. Christman
Citigroup Payment Services
Cold Spring Harbor Laboratory
Community Foundation of New Jersey
Mr. Desmond M. Cooke
Craig Michael Plunkett Revocable Trust
Vincent Critelli
Croatian American Charitable Foundation
Ms. Melodee R. Davis and Family
Ms. Lucy Delgado
Mr. Brian Deutch
Ms. Mary C. Dix
Dolan Family Fund at the Cleveland Foundation
Dorothy “Dot” Robelen Memorial Fund
Dr. Michael G. Dow
Dr. Joan Egrie
Mr. and Mrs. John T. Evans
Mr. and Mrs. Eugene F. Fama
Mrs. Helene Fortunoff and Mr. Robert Grossman
Frank and Theresa Fiola Joint Trust
Mr. and Mrs. Ronald Frankel
Fraydun Foundation, Inc.
Mrs. Gail Gamboni and Family
Ms. Rita Garland
Gene Armario Family Charitable Fund
Gerstner Family Foundation
Goldman Sachs
Mrs. Rona M. Guidone
Laura and Brian Hull
IBM Employee Charitable Contribution Campaign
Immunovia
Ms. Jacqueline Jackson
Johnson & Johnson Matching Gifts Program
Joseph Arena and Dr. Thomas D’Eletto Charitable Fund
JP Morgan Chase
J.T. Hobby Jr. Endowment Fund
Judy Field Memorial Foundation, Inc.
Mr. and Mrs. Michael Kabat
Mr. Christopher Kete and Ms. Tiffany George-Kete
Mr. and Mrs. William Hunter Kleh
Mr. and Mrs. Kenneth H. Klein
Mr. Howard M. Krams
Ms. Tricia Lehmann
Mr. Paul Leinwand
Linda M. Cote Charitable Fund
Dr. Edward F. Loeb and Family
Mr. Thomas Lund
Mr. and Mrs. Andrew Lustgarten
Ms. Carin Mack
Ms. Leslie Maltz
Mark and Gayle Lerch Family Foundation
Ms. Gloria Marsh
Memorial Healthcare Systems
Merrill Lynch Office Disbursement Account
Michael F. Pasquale Memorial Fund
Mr. and Mrs. Stephen E. Milstein
Mrs. Pranvera Mollabeqiri
Mr. Joseph Moretti
Morgan Stanley
MUFG
National Hockey League
Mrs. Carol Nick
Norma Pace Foundation
Northside Hospital
Nova Construction Services, LLC
Mr. John J. O’Brien
The Paraschac Foundation
ParkerGale, LLC
PJT Partners
Ms. Tracey A. Rivas
Mr. Alan E. Rosenau
Ms. Laura Rossi
Mr. Neil Rossy
Ms. Nancy Roth
Mr. Harvey Rudman
Virginia Grande Schwenk
Severud Associates Consulting Engineers PC
Shearman & Sterling LLP
Ms. Judith Siegfried
Mr. Adam Silver
Stanley Shalom Zielony Foundation
Ms. Susan B. Stearns
Stewart Title Insurance Company
Strategic Wealth Planning, Inc.
Mr. and Mrs. Robert Sturgis
The Charles B. Wang International Foundation
The Clarissa & Edgar Bronfman Jr. Foundation
The Elias Genevieve and Georgianna Atol Charitable Trust
The Ergonomic Group
The Gordon L. Polimer Revocable Trust
The Hildenbrand Family Foundation
The Kessler Family Foundation
The McGovern Family Pancreatic Cancer Awareness Foundation
The Nielsen Company, Inc.
The Peter Grosslight Memorial Fund
The Robert and Marion Schamann Brozowski Foundation
The Schwartz Family Foundation
The Spionkop Charitable Trust
The Sunshine Foundation
The Switzer Group
The Tom and Cathy Edwards Giving Fund
Mr. Anthony V. Thompson
Tom DeBerry Golf Memorial
U.S. Bank
Vornado Realty Trust
Mr. and Mrs. Timothy J. Walsh
Wells Fargo Bank
Mrs. Cassie Wence
Hope and Gavin Wolfe
Mr. Mike D. Yantis and Family
Benefactor Circle
$5,000–$9,999

A & E Television Networks
Act For NIH Foundation
Mr. and Mrs. James Albers
Allstate
AmazonSmile Foundation
America’s Charities
Amir & Rosita Manocherian Family Foundation
Ancient Order of Hibernians Division #2
Mr. Sig Anderman
Approved Oil Company
Mr. Marco Argenti
AT&T - YourCause
Aurora Policemen Credit Union
Bahnik Foundation, Inc.
Mrs. Holly Bakke and Family
Baldor Specialty Foods Inc.
Mrs. Evelyn Barrow
Mr. Phillip Battista
Ms. Lillian Baumann
Bernice and David Gotlieb Philanthropic Fund
Stephen Bernstein
Blackedge Capital
Blake, Cassels & Graydon LLP
Mr. and Mrs. Richard Blomquist
Mr. Jay R. Bloom
BNGF J. Horowitz and E. Hardin Fund
Brend Restoration LLC
Mr. John F. Campbell
Canter for the Cure
Capital Group Companies
Capobianco Engineering Group, LLP
Carol & Jack Kline Fund
Mr. and Mrs. Robert B. Catell
Mrs. Gabrielle Cioffi-Kogod
Ms. Alana Clegg
Clifton Budd & DeMaria LLP
Mr. Hans D. Colflesh
Mrs. Georgia Cooper
Mr. and Mrs. Gary Damast
Mr. Jeffrey M. Day
Mr. and Mrs. Thomas F. DeGrazia
Mr. and Mrs. Michael S. Dernburg
Mr. and Mrs. Peter Desmond
Mr. Peter Dimon
Doyle & McKean LLP
Edward Darman Co., L.P.
Mrs. Gail R. Eisenberg
Epic Charitable Fund
Fifth Avenue of L.I. Realty Association
First Republic Bank
Floors for the Cure Foundation
Ms. Lara Fortunoff
Mr. and Mrs. Michael P. Francesa
Mr. Charles Frankel
Mr. and Mrs. James A. Fraser
FSI Architecture PC
Ms. Jennifer Fuller
Mr. Roy S. Gilbert and Family
Gleason Family Foundation, Inc.
Mr. Randy E. Glick
Mrs. Sherry Gold
Good Hope Foundation
Granite Gives Back, Inc.
Mr. Todd S. Greenberg
Ms. Jane Griffith
Allen and Deborah Grubman
Mr. Richard Gruen
Christopher J. Hagen
Hallador Partners
Mr. Stephen Hanson
Harold Kramer Foundation
Harold M. & Mary B. Morris Charitable Foundation Inc.
Mr. Roger Hathaway
Mr. and Mrs. Jason Heckman
Mr. Merrit Heminway
Henkel Corporation
Hercules Corporation
Mr. Ronald Hohmann Sr.
Mr. James Holzhauer
iHeart Media
Ms. Rebecca P. Ilog
Info Quick Solutions Inc.
Insperity Services, L.P. Operating Account
Inter Renovation, Inc.
International Benefits Administrators LLC
Ms. Beverly S. Jacobs
Mrs. Sylvia Jacobs and Family
J.T. Magen & Company, Inc.
The Kalaydjian Family
Mr. Kerry J. Kirby
Mr. Michael T. Koltz
Mr. Philip Krejci
Ms. Michelle R. Kunerth
Mrs. Joan B. Lane
Mrs. Carol Lattimer
Mr. and Mrs. Michael E. Laub
Lawton Adams Construction
Mr. John Laxmi and Ms. Diane Laxmi
Ms. Marianne Lazarou-Benjamin
Leahey & Johnson, P.C.
Lee Watchtower Charitable Fund
Mr. Steve Leonard
Mrs. Iris C. Lerner
Leslie C. Quick, Jr. & Regina A. Quick Charitable Foundation
Mr. Richard H. Leung
Mr. and Mrs. Richard P. Levy
Mr. and Mrs. Aaron Linsky
LLC Trustee for New York Life—YourCause
L’Oreal YourCause, LLC Trustee for L’Oreal USA
Ms. Helen Lowenstein
Jeanine Lunardi
Lydia K. Feidler Charitable Trust
M&L Russo Family Foundation
Mafsi Region 3
Mr. and Mrs. Joseph Mancino
Margot and Howard Steinberg Charitable Foundation
Mr. Jason Medenceles
Mr. and Mrs. Rich Meisenberg
Mrs. Diane Miller and Family
Mrs. Jean Miller
Montauk Sports, Inc.
Ms. Karen S. Moore
My Tribute Gift Foundation, Inc.
NJ Lenders Corp.
Novocure
Oracle America, Inc.
Oresky & Associates, PLLC
Mrs. Erika L. Padgett and Mr. Tom Padgett
Paypal
Penino & Moynihan, LLP
Ms. Kim Perretta
Mr. and Mrs. Jeffrey L. Pliskin
Power Design Inc.
Mr. John J. Powers
Mr. and Mrs. Salvatore J. Pranzo and Family
Ms. JoAnn J. Pullen
Mrs. F. F. Randolph Jr.
Mr. Warren A. Richardson
Mr. Christian Riepe
Mr. Marc Rossi
Ms. Francis J. Roth
Mr. James B. Rowley
Patron Circle
$2,500–$4,999
21st Century Oncology, Inc.
AbbVie
Mr. Laurence J. Abzug
AIG Matching Grants Program
Alliance Bernstein, LP, YourCause
American Express Foundation
Employee Gift & Matching Program
Mrs. Quinta E. Andersen
Ms. Gretchen M. Anderson
Bank of America Charitable Foundation
Mr. Paul A. Becker
Mrs. Joann M. Bedard
Mr. Frank Bendl
Ms. Michelle Bernstein
Bloomberg L.P.
BMB Solutions
Ms. Mary D. Bodenstein
Mr. Peter N. BonTempo, Jr.
Mrs. Marie Brausam
Bristol Myers Squibb Foundation
Mr. Richard Bronstein and Mrs. Eileen Silvers
Erlwein and Matthew Brumm
Mr. William Bruner and Family
Mr. Thomas Buonaiuto
Ms. Elise Caira
Mr. Gary A. Chanowitz
Citrin Cooperman & Company, LLP
Ms. Karen J. Clananhan
Clearpool Group
Mrs. Carol Y. Cohen
Ms. Sharon M. Cohen
Mrs. Carol Collins
Ms. Gillian Cooper
Covington & Burling LLP
Mr. Robert H. Cox
Credit Suisse First Boston
Ms. Sandra Cunningham
Daniell Family Foundation Inc.
Jeff and Sharee Danker
John and Shelley Day
Ms. Kally Dennig
Disney Worldwide Services, Inc.
DLA Piper LLC
Mr. and Mrs. Adam Donner
Ms. Joan Eigen
Mr. Stephen F. Ellison
Mr. and Mrs. David O. Eng
Mr. Frederick W. Engel
Ms. Karen Erlwein
Fairway Golf, Inc.
Mr. David D. Fero
Mrs. Brian Flanagan
Fleishhacker Foundation
Mrs. Amanda B. Flicker and Mr. Corey Moyer
Mrs. Ruth Fortunoff-Cooper and Mr. Brian Cooper
Ms. Sharon Fressle
Anita Dann Friedman & Harvey Friedman
Fross Zelnick Lehrman & Zissu, P.C.
Mr. Heath Fuller
Mr. Walter F. Gajdzis
Mr. and Mrs. Gregory G. Gannon
Cindy and Brian Gavin
Mr. and Mrs. Paul Geiger
Abdel and Barbara Ghafari
Mr. Josh Gillon and Family
Ms. Gail Gittleson
Glen Oaks Club
Mr. and Mrs. Steve Goldberg
Goldman Sachs Matching Gift Program
Ms. Stacy Goodman
GPG Properties
Mr. August Greidanus
Ms. Laura Grim
Ms. Samantha Handler
Mr. Adam Handwerker
Hauser’s Truck Service, Inc.
Haynes and Boone, LLP
Mr. William Henson
Mr. and Mrs. David S. Hershberg
Hershey Family Fund
Mrs. Inge M. Horn
Mrs. Loretta E. Howard
Ms. Silvia Hughes
JFK Medical Staff, Inc.—JFK Medical Center
Johnson Family Fund
Ms. Sarah M. Johnson
JPMC Foundation
Mr. Jeffrey Kan
Kasirer Consulting
KPMG Community Giving Campaign
Ms. Alicia E. Kraemer
Mr. and Mrs. Raymond G. Kunz
Ms. Carol A. Lace
Latham & Watkins LLP
Leonard Park Wines & Spirits, LLC

26 Annual Report 2020
Mr. Steve Leonard
Ron and Ilene Lesser
Joshua and Shanea Leven
Mrs. Elizabeth P. Levengood
Mr. and Mrs. Robert Litterman
Louis and Tobey Lipschitz
Charitable Fund
LTC Global, Inc.
Ms. Carol Ludwig
Lynn and Jules Kroll Family Foundation, Inc.
Mrs. Jill Magidson
Ms. Ruth Mathew
Mr. Doug McDaniel
Ms. Nancy L. Miller
Moffitt Cancer Center
Mr. and Mrs. Craig Moore
Ms. Emily Naderi
Mr. Derek Oberman
O'Connor Foundation
Old Westbury Golf & Country Club
Omega Phi
Oritani Bank Charitable Foundation
Mrs. Marilyn J. Palmer
Pascucci Family Foundation
Michael Pasquale
Mr. James Pasquarette
Mr. William G. Paullin
Peter and Patti Hill Charitable Fund
Pfizer Foundation Matching Gifts Program - YourCause
Pine Hollow Charity Fund, Inc.
Mr. Jack R. Pine
Pledgeling Foundation
Mr. and Mrs. Jeffrey L. Pliskin
Mr. Nathan T. Pruitt
PSEG Long Island, LLC
pwc by YourCause, LLC
R. Keith Butterfield Memorial Fund
Raising Hope for Others
Gil and Emily Raviv
Mr. Arthur Rettinger and Ms. Debra Schwartz
Ms. Margaret R. Riemer
Mr. Schuyler Risk
RMAS Rising Stars
Mrs. Betty M. Roach
Robert Colleran Charitable Gift Fund
Ms. Lauren Roberts
Mr. and Mrs. Raymond W. Ross
Ms. Atoosa Rubenstein
Ms. Debra Samuelson
Mr. James R. Sarka
Mrs. Marlene Sauer
Mr. Noam Schaap
Schulze & Burch Biscuit Co.
Scott Hamilton CARES Foundation
Mr. Mike Seaworth
Ms. Nancy Sebok
Mr. Timothy Seck
Sederberg-Calk Charitable Fund
Mr. Bruce E. Seibert
Ms. Willa Shalit and Mr. A. James Heynen
Mr. Thomas Shapiro
Mr. Ben Shapiro-Kline
Signature Bank
Devon and Michael Silberstein
Reverend William T. Slater
Jack and Bonnie Smailies
Dr. Robert Stannard
Mrs. Gail Stanton
Mr. Keith Stechmesser
Dr. Zelig Steinberg and Mrs. Pamela J. Steinberg
Mr. Robert Stone
Stuart and Nancy Friedell Family Foundation
Mr. Frank P. Terzo
TG Window Coverings, Inc.
The Aboodi & Hoffman Families
The Bowling Family Foundation
The Boyce Family Fund of the Philadelphia Foundation
The Dorfman & Kaish Family
The Feurring Foundation
The Fressle Family Fund
The Gettinger Family Foundation
The Odierno Law Firm P.C.
The Stop & Stor Charitable Fund
The Tara and Arthur Goldfrank Fund
The Weinreb-Berenda-Carter Foundation Inc.
The William & Flora Hewlett Foundation Matching Gifts Program
Theodore and Karin Mayer Family Foundation
Ms. Nancy L. Thomsen
Jayne Thornton
Mr. Robert S. Trump
UBS Financial Services Inc.
Valley Hospital
Constance & Anthony J. Vela
Ms. Elizabeth G. Verville
Ms. Alexanderina Vigh
Mrs. Chris Viola-Weiss
Walden Macht & Haran LLP
Ms. Irene M. Walsten
Wayne Cohen, M.D. PLLC
Mrs. Kathleen Wehrman
Pepi Weis
Mr. and Mrs. Larry B. Weissenberg
Ms. Joanie Wieleba
Mrs. Kristine Wilson
Ms. Megan Wisdom
Ms. Elizabeth Worley
Mr. and Mrs. John Yokim

This donor list has been prepared with the greatest of care. We sincerely regret any errors or omissions. If you have questions about this list, please contact us at 866.789.1000.

This listing reflects the total amount of donors’ commitments from July 1, 2019–June 30, 2020. Donations amounting to $1,000-$2,499 received between July 1, 2019–June 30, 2020 are available at www.lustgarten.org.

Your support gives pancreatic cancer patients and their families hope that breakthroughs are within reach.
Thank you to the nearly 230 donors who have joined Partners in Progress, a dedicated group of supporters who generously choose to make a monthly gift to the Lustgarten Foundation. Your monthly contributions help fund life-saving research studies and clinical trials, enhance patient services and ensure even more time, talent and resources are devoted to discovering the best treatments and early detection methods. Partners in Progress donors are invited to connect in an exclusive Facebook group, where members share their personal stories and engage with other supporters equally committed to finding a cure. To join the Partners in Progress monthly giving circle, contact us at 866.789.1000.
LEADERSHIP

Lustgarten Leadership

BOARD OF DIRECTORS:

Andrew Lustgarten
Chairman, Lustgarten Foundation;
President and CEO, MSG Sports;
President, MSG Entertainment

James L. Dolan
Vice Chairman, Lustgarten Foundation;
Executive Chairman and CEO, MSG Entertainment/MSG Sports;
Executive Chairman, MSG Networks

Adam Silver
Vice Chairman, Lustgarten Foundation;
Commissioner, National Basketball Association

Charles F. Dolan
Chairman Emeritus, Lustgarten Foundation;
Chairman Emeritus, AMC Networks;
Former Chairman, Cablevision Systems Corporation

William Bell
Treasurer, Lustgarten Foundation;
Former Vice Chairman, Cablevision Systems Corporation

John Cobb
Partner, Paul Hastings

Jessica Courtemanche
Vice President/Director, Data and Analysis, Digitas

Quentin Dolan
Director, MSG Networks

Jennie Fortunoff
Principal, Esterow Events & Consulting, Inc.

Kenneth Goodman, M.D., F.A.C.R.
Former Director, Department of Radiology and Attending Physician, St. Francis Hospital

Kerri Kaplan
President, Lustgarten Foundation

Marcia Lustgarten
Former Director, Optimum Community, Cablevision Systems Corporation

Sheila Mahony
Former Executive Vice President, Communication, Government and Public Affairs, Cablevision Systems Corporation

John O’Brien (term ended 6/30/20)
President, O’Brien Partners

Charles R. Schueler
Former Executive Vice President, Media and Community Relations, Cablevision Systems Corporation

Willa Shalit
Co-Founder and Principal, RTM Limited;
Co-Founder, Let’s Win! Pancreatic Cancer

Linda Tantawi
CEO, Lustgarten Foundation

CORPORATE ADVISORY BOARD:

The Honorable Jimmy Carter
39th U.S. President, Honorary Chairman

Frank A. Bennack Jr.
Executive Vice Chairman and Former Chief Executive Officer, Hearst Corporation

Barry Diller
Chairman of the Board and Senior Executive, Expedia Group and IAC/InterActiveCorp; Founder, Fox Broadcasting and USA Broadcasting

John S. Hendricks
Founder and Former Chairman, Discovery Communications; Founder, CuriosityStream

Mel Karmazin
Former Chief Executive Officer, Sirius XM Radio; Co-Founder, Infinity Broadcasting

Gerald M. Levin
Former Chairman and Chief Executive Officer, Time Warner, Inc.; Chairman, Dialyze Innovation Group

John C. Malone
Former Chief Executive Officer, Tele-Communications Inc.; Chairman, Liberty Media, Liberty Global and Qurate Retail Group

Rupert Murdoch
Executive Chairman, News Corp;
Chairman, Fox Corporation

Tom Rogers
Executive Chairman, Engine Media;
Founder, CNBC

Sir Howard Stringer
Non-Executive Director, British Broadcasting Corporation;
Former Chairman of the Board, Sony Corporation

SCIENTIFIC ADVISORY BOARD:

James Abbruzzese, M.D.
Duke University School of Medicine

Ronald M. Evans, Ph.D.
Salk Institute for Biological Studies

Douglas T. Fearon, M.D.
Cold Spring Harbor Laboratory and Well Cornell Medicine

Charles S. Fuchs, M.D., MPH
Yale Cancer Center and Smilow Cancer Hospital

Tyler Jacks, Ph.D.
Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology

Elizabeth M. Jaffee, M.D.
Chief Medical Advisor, Lustgarten Foundation; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

David Paul Kelsen, M.D.
Memorial Sloan Kettering Cancer Center

Robert J. Mayer, M.D.
Dana-Farber Cancer Institute and Harvard Medical School

Bruce Stillman, Ph.D.
Cold Spring Harbor Laboratory

David A. Tuveson, M.D., Ph.D.
Chief Scientist, Lustgarten Foundation; Cold Spring Harbor Laboratory

Bert Vogelstein, M.D.
The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brian Wolpin, M.D., MPH
Dana-Farber Cancer Institute and Harvard Medical School
OUR MISSION IS TO CURE PANCREATIC CANCER BY:

• funding scientific and clinical research related to the diagnosis, treatment and prevention of pancreatic cancer;

• providing research information and clinical support services to patients, caregivers and individuals at high risk; and

• increasing public awareness and hope for those dealing with this disease.

The Lustgarten Foundation envisions a world in which pancreatic cancer is curable and patients will be treated effectively and enjoy a better quality of life.

100% of your donation funds pancreatic cancer research.